Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. more
Time Frame | TNGX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -12.08% | -3.39% | 0.2% |
1-Month Return | -19.17% | -1.92% | 2.72% |
3-Month Return | -66.24% | -10.54% | 7.31% |
6-Month Return | -68.98% | -4.47% | 10.44% |
1-Year Return | -72.02% | 4.06% | 27.53% |
3-Year Return | -73.55% | 0.94% | 30.88% |
5-Year Return | -71.55% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 24.65M | 7.66M | 37.04M | 24.86M | 36.53M | [{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":20.67,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":67.11,"profit":true},{"date":"2023-12-31","value":98.61,"profit":true}] |
Cost of Revenue | 31.46M | 1.63M | 1.97M | 4.03M | 115.20M | [{"date":"2019-12-31","value":27.31,"profit":true},{"date":"2020-12-31","value":1.41,"profit":true},{"date":"2021-12-31","value":1.71,"profit":true},{"date":"2022-12-31","value":3.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (6.81M) | 6.03M | 37.04M | 24.86M | (78.67M) | [{"date":"2019-12-31","value":-18.38,"profit":false},{"date":"2020-12-31","value":16.28,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":67.11,"profit":true},{"date":"2023-12-31","value":-212.38,"profit":false}] |
Gross Margin | (27.62%) | 78.77% | 100.00% | 100.00% | (215.38%) | [{"date":"2019-12-31","value":-27.62,"profit":false},{"date":"2020-12-31","value":78.77,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-215.38,"profit":false}] |
Operating Expenses | 7.97M | 59.86M | 95.23M | 135.93M | 150.70M | [{"date":"2019-12-31","value":5.29,"profit":true},{"date":"2020-12-31","value":39.72,"profit":true},{"date":"2021-12-31","value":63.19,"profit":true},{"date":"2022-12-31","value":90.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (15.16M) | (52.20M) | (58.19M) | (111.07M) | (114.17M) | [{"date":"2019-12-31","value":-1516200000,"profit":false},{"date":"2020-12-31","value":-5220000000,"profit":false},{"date":"2021-12-31","value":-5819000000,"profit":false},{"date":"2022-12-31","value":-11107100000,"profit":false},{"date":"2023-12-31","value":-11417300000,"profit":false}] |
Total Non-Operating Income/Expense | - | 336.00K | 742.00K | 4.41M | 17.54M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":1.92,"profit":true},{"date":"2021-12-31","value":4.23,"profit":true},{"date":"2022-12-31","value":25.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (14.10M) | (51.97M) | (57.94M) | (108.12M) | (101.61M) | [{"date":"2019-12-31","value":-1409500000,"profit":false},{"date":"2020-12-31","value":-5197200000,"profit":false},{"date":"2021-12-31","value":-5794300000,"profit":false},{"date":"2022-12-31","value":-10812200000,"profit":false},{"date":"2023-12-31","value":-10161000000,"profit":false}] |
Income Taxes | - | (108.00K) | 292.00K | 54.00K | 134.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-36.99,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":18.49,"profit":true},{"date":"2023-12-31","value":45.89,"profit":true}] |
Income After Taxes | - | (51.86M) | (58.23M) | (108.18M) | (101.74M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5186400000,"profit":false},{"date":"2021-12-31","value":-5823500000,"profit":false},{"date":"2022-12-31","value":-10817600000,"profit":false},{"date":"2023-12-31","value":-10174400000,"profit":false}] |
Income From Continuous Operations | - | (51.97M) | (58.23M) | (108.18M) | (100.04M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5197200000,"profit":false},{"date":"2021-12-31","value":-5823500000,"profit":false},{"date":"2022-12-31","value":-10817600000,"profit":false},{"date":"2023-12-31","value":-10004100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (14.10M) | (51.86M) | (58.23M) | (108.18M) | (101.74M) | [{"date":"2019-12-31","value":-1409500000,"profit":false},{"date":"2020-12-31","value":-5186400000,"profit":false},{"date":"2021-12-31","value":-5823500000,"profit":false},{"date":"2022-12-31","value":-10817600000,"profit":false},{"date":"2023-12-31","value":-10174400000,"profit":false}] |
EPS (Diluted) | - | (0.01) | (0.70) | (1.23) | (1.10) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.58,"profit":false},{"date":"2021-12-31","value":-70,"profit":false},{"date":"2022-12-31","value":-123,"profit":false},{"date":"2023-12-31","value":-110,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TNGX | |
---|---|
Cash Ratio | 7.80 |
Current Ratio | 8.00 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TNGX | |
---|---|
ROA (LTM) | -22.37% |
ROE (LTM) | -48.79% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TNGX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.35 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.65 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TNGX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 7.21 |
P/B | 1.36 |
Price/FCF | NM |
EV/R | 1.31 |
EV/Ebitda | NM |
Tango Therapeutics Inc (TNGX) share price today is $2.842
Yes, Indians can buy shares of Tango Therapeutics Inc (TNGX) on Vested. To buy Tango Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TNGX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Tango Therapeutics Inc (TNGX) via the Vested app. You can start investing in Tango Therapeutics Inc (TNGX) with a minimum investment of $1.
You can invest in shares of Tango Therapeutics Inc (TNGX) via Vested in three simple steps:
The 52-week high price of Tango Therapeutics Inc (TNGX) is $13.01. The 52-week low price of Tango Therapeutics Inc (TNGX) is $2.7.
The price-to-earnings (P/E) ratio of Tango Therapeutics Inc (TNGX) is
The price-to-book (P/B) ratio of Tango Therapeutics Inc (TNGX) is 1.36
The dividend yield of Tango Therapeutics Inc (TNGX) is 0.00%
The market capitalization of Tango Therapeutics Inc (TNGX) is $312.59M
The stock symbol (or ticker) of Tango Therapeutics Inc is TNGX